Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1045 to 1052 of 1052 entries
Sorted by: Best Match Show Resources per page
Reducing SARS-CoV-2 pathological protein activity with small molecules.

Journal of pharmaceutical analysis

Pluskota-Karwatka D, Hoffmann M, Barciszewski J.
PMID: 33842018
J Pharm Anal. 2021 Aug;11(4):383-397. doi: 10.1016/j.jpha.2021.03.012. Epub 2021 Apr 05.

Coronaviruses are dangerous human and animal pathogens. The newly identified coronavirus SARS-CoV-2 is the causative agent of COVID-19 outbreak, which is a real threat to human health and life. The world has been struggling with this epidemic for about...

Cite
Pluskota-Karwatka D, Hoffmann M, Barciszewski J. Reducing SARS-CoV-2 pathological protein activity with small molecules. J Pharm Anal. 2021;11(4):383-397doi: 10.1016/j.jpha.2021.03.012.
Pluskota-Karwatka, D., Hoffmann, M., & Barciszewski, J. (2021). Reducing SARS-CoV-2 pathological protein activity with small molecules. Journal of pharmaceutical analysis, 11(4), 383-397. https://doi.org/10.1016/j.jpha.2021.03.012
Pluskota-Karwatka, Donata, et al. "Reducing SARS-CoV-2 pathological protein activity with small molecules." Journal of pharmaceutical analysis vol. 11,4 (2021): 383-397. doi: https://doi.org/10.1016/j.jpha.2021.03.012
Pluskota-Karwatka D, Hoffmann M, Barciszewski J. Reducing SARS-CoV-2 pathological protein activity with small molecules. J Pharm Anal. 2021 Aug;11(4):383-397. doi: 10.1016/j.jpha.2021.03.012. Epub 2021 Apr 05. PMID: 33842018; PMCID: PMC8020608.
Copy Download .nbib Format: NLM
Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.

The Journal of dermatology

Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, Personke Y, Gomez M, Sticherling M.
PMID: 34510527
J Dermatol. 2021 Dec;48(12):1854-1862. doi: 10.1111/1346-8138.16128. Epub 2021 Sep 12.

Psoriasis is a common, chronic inflammatory skin disorder negatively impacting health-related quality of life (HRQoL). Guselkumab, targeting interleukin-23 (IL-23), is an approved biologic therapy for psoriasis. PERSIST is an ongoing prospective, noninterventional, long-term, German multicenter study evaluating the effect...

Cite
Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854-1862doi: 10.1111/1346-8138.16128.
Gerdes, S., Bräu, B., Hoffmann, M., Korge, B., Mortazawi, D., Wiemers, F., Wegner, S., Personke, Y., Gomez, M., & Sticherling, M. (2021). Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. The Journal of dermatology, 48(12), 1854-1862. https://doi.org/10.1111/1346-8138.16128
Gerdes, Sascha, et al. "Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial." The Journal of dermatology vol. 48,12 (2021): 1854-1862. doi: https://doi.org/10.1111/1346-8138.16128
Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, Personke Y, Gomez M, Sticherling M. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021 Dec;48(12):1854-1862. doi: 10.1111/1346-8138.16128. Epub 2021 Sep 12. PMID: 34510527.
Copy Download .nbib Format: NLM
US FDA best practices for initiating early feasibility studies for neurological devices in the United States.

Journal of neurosurgery

Herrmann R, Dreher M, Farb A, Hoffmann M, Loftus CM, Mezu-Nwaba N, Pinto V, Zheng X, Peña C.
PMID: 34087794
J Neurosurg. 2021 Jun 04;136(1):282-286. doi: 10.3171/2020.11.JNS203653. Print 2022 Jan 01.

This article describes the efforts of the US Food and Drug Administration (FDA) Office of Neurological and Physical Medicine Devices to facilitate early clinical testing of potentially beneficial neurological devices in the US. Over the past 5 years, the...

Cite
Herrmann R, Dreher M, Farb A, et al. US FDA best practices for initiating early feasibility studies for neurological devices in the United States. J Neurosurg. 2021;136(1):282-286doi: 10.3171/2020.11.JNS203653.
Herrmann, R., Dreher, M., Farb, A., Hoffmann, M., Loftus, C. M., Mezu-Nwaba, N., Pinto, V., Zheng, X., & Peña, C. (2022). US FDA best practices for initiating early feasibility studies for neurological devices in the United States. Journal of neurosurgery, 136(1), 282-286. https://doi.org/10.3171/2020.11.JNS203653
Herrmann, Robert, et al. "US FDA best practices for initiating early feasibility studies for neurological devices in the United States." Journal of neurosurgery vol. 136,1 (2022): 282-286. doi: https://doi.org/10.3171/2020.11.JNS203653
Herrmann R, Dreher M, Farb A, Hoffmann M, Loftus CM, Mezu-Nwaba N, Pinto V, Zheng X, Peña C. US FDA best practices for initiating early feasibility studies for neurological devices in the United States. J Neurosurg. 2021 Jun 04;136(1):282-286. doi: 10.3171/2020.11.JNS203653. Print 2022 Jan 01. PMID: 34087794.
Copy Download .nbib Format: NLM
Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis.

Molecular psychiatry

Wilke JBH, Hindermann M, Berghoff SA, Zihsler S, Arinrad S, Ronnenberg A, Barnkothe N, Steixner-Kumar AA, Röglin S, Stöcker W, Hollmann M, Nave KA, Lühder F, Ehrenreich H.
PMID: 34331009
Mol Psychiatry. 2021 Jul 30; doi: 10.1038/s41380-021-01238-3. Epub 2021 Jul 30.

The etiology and pathogenesis of "anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis" and the role of autoantibodies (AB) in this condition are still obscure. While NMDAR1-AB exert NMDAR-antagonistic properties by receptor internalization, no firm evidence exists to date that NMDAR1-AB by themselves induce...

Cite
Wilke JBH, Hindermann M, Berghoff SA, et al. Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis. Mol Psychiatry. 2021;doi: 10.1038/s41380-021-01238-3.
Wilke, J. B. H., Hindermann, M., Berghoff, S. A., Zihsler, S., Arinrad, S., Ronnenberg, A., Barnkothe, N., Steixner-Kumar, A. A., Röglin, S., Stöcker, W., Hollmann, M., Nave, K. A., Lühder, F., & Ehrenreich, H. (2021). Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis. Molecular psychiatry, . https://doi.org/10.1038/s41380-021-01238-3
Wilke, Justus B H, et al. "Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis." Molecular psychiatry vol. (2021). doi: https://doi.org/10.1038/s41380-021-01238-3
Wilke JBH, Hindermann M, Berghoff SA, Zihsler S, Arinrad S, Ronnenberg A, Barnkothe N, Steixner-Kumar AA, Röglin S, Stöcker W, Hollmann M, Nave KA, Lühder F, Ehrenreich H. Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis. Mol Psychiatry. 2021 Jul 30; doi: 10.1038/s41380-021-01238-3. Epub 2021 Jul 30. PMID: 34331009.
Copy Download .nbib Format: NLM
Early-Age Mechanical Properties of 3D-Printed Mortar with Spent Garnet.

Materials (Basel, Switzerland)

Skibicki S, Jakubowska P, Kaszyńska M, Sibera D, Cendrowski K, Hoffmann M.
PMID: 35009250
Materials (Basel). 2021 Dec 23;15(1). doi: 10.3390/ma15010100.

This study determines the effect of spent garnet as a replacement for natural sand in 3D-printed mortar at early ages. Five mixes with different spent garnet amounts were prepared (0%, 25%, 50%, 75% and 100% by volume). The ratio...

Cite
Skibicki S, Jakubowska P, Kaszyńska M, et al. Early-Age Mechanical Properties of 3D-Printed Mortar with Spent Garnet. Materials (Basel). 2021;15(1)doi: 10.3390/ma15010100.
Skibicki, S., Jakubowska, P., Kaszyńska, M., Sibera, D., Cendrowski, K., & Hoffmann, M. (2021). Early-Age Mechanical Properties of 3D-Printed Mortar with Spent Garnet. Materials (Basel, Switzerland), 15(1), . https://doi.org/10.3390/ma15010100
Skibicki, Szymon, et al. "Early-Age Mechanical Properties of 3D-Printed Mortar with Spent Garnet." Materials (Basel, Switzerland) vol. 15,1 (2021). doi: https://doi.org/10.3390/ma15010100
Skibicki S, Jakubowska P, Kaszyńska M, Sibera D, Cendrowski K, Hoffmann M. Early-Age Mechanical Properties of 3D-Printed Mortar with Spent Garnet. Materials (Basel). 2021 Dec 23;15(1). doi: 10.3390/ma15010100. PMID: 35009250.
Copy Download .nbib Format: NLM
Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1.

Cell research

Hoffmann M, Pöhlmann S.
PMID: 34903854
Cell Res. 2021 Dec 13; doi: 10.1038/s41422-021-00603-9. Epub 2021 Dec 13.

No abstract available.

Cite
Hoffmann M, Pöhlmann S. Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1. Cell Res. 2021;doi: 10.1038/s41422-021-00603-9.
Hoffmann, M., & Pöhlmann, S. (2021). Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1. Cell research, . https://doi.org/10.1038/s41422-021-00603-9
Hoffmann, Markus, and Pöhlmann, Stefan. "Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1." Cell research vol. (2021). doi: https://doi.org/10.1038/s41422-021-00603-9
Hoffmann M, Pöhlmann S. Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1. Cell Res. 2021 Dec 13; doi: 10.1038/s41422-021-00603-9. Epub 2021 Dec 13. PMID: 34903854.
Copy Download .nbib Format: NLM
VECSEL gain characterization.

Optics express

Mangold M, Wittwer VJ, Sieber OD, Hoffmann M, Krestnikov IL, Livshits DA, Golling M, Südmeyer T, Keller U.
PMID: 22418171
Opt Express. 2012 Feb 13;20(4):4136-48. doi: 10.1364/OE.20.004136.

We present the first full gain characterization of two vertical external cavity surface emitting laser (VECSEL) gain chips with similar designs operating in the 960-nm wavelength regime. We optically pump the structures with continuous-wave (cw) 808-nm radiation and measure...

Cite
Mangold M, Wittwer VJ, Sieber OD, et al. VECSEL gain characterization. Opt Express. 2012;20(4):4136-48doi: 10.1364/OE.20.004136.
Mangold, M., Wittwer, V. J., Sieber, O. D., Hoffmann, M., Krestnikov, I. L., Livshits, D. A., Golling, M., Südmeyer, T., & Keller, U. (2012). VECSEL gain characterization. Optics express, 20(4), 4136-48. https://doi.org/10.1364/OE.20.004136
Mangold, Mario, et al. "VECSEL gain characterization." Optics express vol. 20,4 (2012): 4136-48. doi: https://doi.org/10.1364/OE.20.004136
Mangold M, Wittwer VJ, Sieber OD, Hoffmann M, Krestnikov IL, Livshits DA, Golling M, Südmeyer T, Keller U. VECSEL gain characterization. Opt Express. 2012 Feb 13;20(4):4136-48. doi: 10.1364/OE.20.004136. PMID: 22418171.
Copy Download .nbib Format: NLM
Factors influencing publication of scientific articles derived from masters theses in public health.

Hollmann M, Borrell C, Garin O, Fernandez E, Alonso J.
UIID-AD: 241
2015;60:495-504. doi: 10.1007/s00038-015-0664-0.

To evaluate theses of a Masters program in Public Health (MPH), in terms of the students' and theses' characteristics that influence publication of the thesis as a scientific article. Longitudinal study of students who successfully completed the MPH at...

Cite
Hollmann M, Borrell C, Garin O, et al. Factors influencing publication of scientific articles derived from masters theses in public health. 2015;60:495-504doi: 10.1007/s00038-015-0664-0.
Hollmann, M., Borrell, C., Garin, O., Fernandez, E., & Alonso, J. (2015). Factors influencing publication of scientific articles derived from masters theses in public health. 60495-504. https://doi.org/10.1007/s00038-015-0664-0
Hollmann, M, et al. "Factors influencing publication of scientific articles derived from masters theses in public health." vol. 60 (2015): 495-504. doi: https://doi.org/10.1007/s00038-015-0664-0
Hollmann M, Borrell C, Garin O, Fernandez E, Alonso J. Factors influencing publication of scientific articles derived from masters theses in public health. 2015;60:495-504. doi: 10.1007/s00038-015-0664-0. UIID-AD: 241.
Copy Download .nbib Format: NLM
Showing 1045 to 1052 of 1052 entries